Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma

Annals of Hematology

Volumn 91, Issue 5, 2012, Pages 687-695

  Hong, Junshik ^a   Lee, Yukyung ^a   Park, Yeonjeong ^a   Kim, Seog Gyun ^a   Hwang, Kyung Hoon ^a   Park, Soon Ho ^a   Jeong, Jihoon ^a   Kim, Kyung Hee ^a   Ahn, Jeong Yeal ^a   Park, Sanghui ^a   Park, Jinny ^a   Lee, Jae Hoon ^a  

^a Gachon University   (South Korea)

Author keywords

Bone marrow; Diffuse large B cell lymphoma; FDG PET CT; Lymphoma

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISOLONE; RITUXIMAB; VINCRISTINE; DIAGNOSTIC AGENT;

ADULT; BONE MARROW BIOPSY; BONE MARROW DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR VOLUME; AGED; ARTICLE; BIOPSY; BONE MARROW; BONE MARROW CANCER; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; SCINTISCANNING; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BONE MARROW; BONE MARROW NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84861471316     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1353-6     Document Type: Review

References (23)

1. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31(11):1860-1861
2. Conlan MG, Bast M, Armitage JO, Weisenburger DD (1990) Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol 8(7):1163-1172 (Pubitemid 20195626)
3. Wang J, Weiss LM, Chang KL, Slovak ML, Gaal K, Forman SJ, Arber DA (2002) Diagnostic utility of bilateral bone marrow examination: significance of morphologic and ancillary technique study in malignancy. Cancer 94(5):1522-1531 (Pubitemid 34212647)
4. Hustinx R, Benard F, Alavi A (2002) Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med 32(1):35-46 (Pubitemid 34112941)
5. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579-586 (Pubitemid 350002966)
6. Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio JA, Zhuang H, Pitsilos S, Bagg A, Downs L, Mehrotra A, Kim S, Alavi A, Schuster SJ (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101(10):3875-3876 (Pubitemid 36857861)
7. Fuster D, Chiang S, Andreadis C, Guan L, Zhuang H, Schuster S, Alavi A (2006) Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma? Nucl Med Commun 27(1):11-15 (Pubitemid 44391834)
8. Pelosi E, Penna D, Douroukas A, Bello M, Amati A, Arena V, Passera R, Bisi G (2010) Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study. Q J Nucl Med Mol Imaging
9. Ribrag V, Vanel D, Leboulleux S, Lumbroso J, Couanet D, Bonniaud G, Auperin A, Masson F, Bosq J, Edeline V, Ferme C, Pigneur F, Schlumberger M (2008) Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/CT and bone marrow biopsy. Eur J Radiol 66(2):325-331 (Pubitemid 351626403)
10. Schaefer NG, Strobel K, Taverna C, Hany TF (2007) Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging 34(1):60-67 (Pubitemid 44885555)
11. Cheng G, Chen W, Chamroonrat W, Torigian DA, Zhuang H, Alavi A (2011) Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients. Eur J Nucl Med Mol Imaging
12. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17(12):3835-3849
13. Gordon H, Sweets HH (1936) A simple method for the silver impregnation of reticulum. Am J Pathol 12(4):541-552
14. Chung R, Lai R, Wei P, Lee J, Hanson J, Belch AR, Turner AR, Reiman T (2007) Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood 110(4):1278-1282 (Pubitemid 47281426)
15. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244
16. Itti E, Juweid ME, Haioun C, Yeddes I, Hamza-Maaloul F, El Bez I, Evangelista E, Lin C, Dupuis J, Meignan M (2010) Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background. J Nucl Med 51(12):1857-1862
17. Kand PG, Tiwari BP, Basu S, Asopa RV, Nayak UN (2010) Exploring the role of FDG-PET in the assessment of bone marrow involvement in lymphoma patients as interpreted by qualitative and semiquantitative disease metabolic activity parameter. Indian J Cancer 47(4):380-384
18. Meignan M, Gallamini A, Haioun C (2009) Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma 50(8):1257-1260
19. Moulin-Romsee G, Hindie E, Cuenca X, Brice P, Decaudin D, Benamor M, Briere J, Anitei M, Filmont JE, Sibon D, de Kerviler E, Moretti JL (2010) (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging 37(6):1095-1105
20. Pelosi E, Penna D, Deandreis D, Chiappella A, Skanjeti A, Vitolo U, Bisi G (2008) FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management. Q J Nucl Med Mol Imaging 52(1):9-16 (Pubitemid 351351040)
21. Hodges GF, Lenhardt TM, Cotelingam JD (1994) Bone marrow involvement in large-cell lymphoma. Prognostic implications of discordant disease. Am J Clin Pathol 101 (3):305-311 (Pubitemid 24089577)
22. Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, Connors JM, Gascoyne RD (2011) Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 29(11):1452-1457
23. Campbell J, Seymour JF, Matthews J, Wolf M, Stone J, Juneja S (2006) The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol 76(6):473-480